The Chromophobe RCC Biomarker Discovery Initiative supports scientific efforts to identify, validate, and develop biomarkers specific to chromophobe renal cell carcinoma, with priority given to projects focusing on metastatic disease. Funding goals will be reviewed annually. If funding goals are not met, funds may roll over to the next year or be reallocated but must be used for research related to chromophobe RCC.

Donations to this fund will support activities that may include, but are not limited to:

Biospecimen collection, processing, and storage
Laboratory analysis of patient samples
Biomarker discovery and validation studies
Data analysis and computational biology support
Collaboration with research institutions and industry partners
Patient engagement and consent processes for sample donation

As specific research opportunities arise, COA will:

Evaluate potential projects against established scientific criteria
Consider both external research proposals and internal initiatives
Prioritize initiatives with potential impact for metastatic chromophobe RCC patients
Publicly announce funding decisions through our website and communications channels
Provide updates on research progress to our community
Ensure transparency in how funds are utilized

This baseline funding level will enable COA to support activities such as:

Funding promising biomarker research projects
Contributing to existing biobanking initiatives
Supporting collaborative biomarker investigation
Advancing research partnerships with institutions studying chromophobe RCC
Catalyzing new investigations into metastatic disease biomarkers

Chromophobe RCC Biomarker Discovery Initiative

By Chromophobe and Oncocytic Tumor Alliance

Chromophobe RCC Biomarker Discovery Initiative

Support scientific efforts to identify, validate, and develop biomarkers specific to chromophobe renal cell carcinoma.

Team Members